Kanzo

Case Report

A case of type C chronic hepatitis with constitutional hyperbilirubinemia treated by peginterferon-alpha+ribavirin+simeprevir

Yoshinori Horie, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Takanori Kanai

2015 Volume 56 Issue 1 Pages 13-17
Published: January 20, 2015
Released on J-STAGE: January 30, 2015

DOIhttps://doi.org/10.2957/kanzo.56.13

JOURNAL FREE ACCESS

Show abstractHide abstract

We reported a case of a 42-y/o man with constitutional hyperbilirubinemia and type C chronic hepatitis treated by peginterferon-alpha+ribavirin+simeprevir. His serum TB level was increased (from 2.5 to 8.1 mg/dL 3 w after treatment), but gradually decreased thereafter (5.1 mg/dL 4 w after treatment), and recovered (3.0 mg/dL) 4 w after stopping simeprevir. HCV-RNA has been negative and liver function has been normal after treatment. He did not have either any symptom or abnormality in laboratory data except TB level during the treatment. Simeprevir was reported to sometimes increase serum TB level. In this case, organic anion-transporting polypeptide 1B1 (OATP1B1) seems to be inhibited by simeprevir, because the increase in indirect bilirubin was dominant. This case suggests that the treatment for type C chronic hepatitis with simeprevir is possible even in patients with constitutional hyperbilirubinemia, because the increase in serum TB level was temporal and recovered after stopping simeprevir.

View full abstract

Download PDF (267K)

Short Communications

Clinical observations of patients who contracted hepatitis B virus infection during childhood and presented with hepatocellular carcinoma until the age of 30 years

Tomoko Takano, Ayano Inui, Kousuke Ushizima, Youko Miyoshi, Daiki Abuk ...

2015 Volume 56 Issue 1 Pages 18-20
Published: January 20, 2015
Released on J-STAGE: January 30, 2015

DOIhttps://doi.org/10.2957/kanzo.56.18

JOURNAL FREE ACCESS

Show abstractHide abstract

In the multi-center study of hepatitis B virus (HBV) infection in children, there were 11 cases of hepatocellular carcinoma (HCC) which were diagnosed during childhood, adolescence and young adulthood. Ten of the 11 were boys and the median age at diagnosis of HCC was 15 years (range, 9-25). Most cases with HCC achieved HBe Ag seroconversion, had a slight elevation of ALT and low values of HBV-DNA. Seven of the 11 with HCC died within one year from diagnosis of HCC. All of the fatal cases had no follow up when HCC was found. HCC may develop in children and young adult with HBV infection, especially after HBe Ag seroconversion. The lifelong follow-up may be mandatory for children with chronic HBV infection.

View full abstract

Download PDF (178K)
Evaluation of the clinical utility of Cobas TaqMan HCV v2.0

Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Hitomi Sezaki, Yusuke ...

2015 Volume 56 Issue 1 Pages 21-23
Published: January 20, 2015
Released on J-STAGE: January 30, 2015

DOIhttps://doi.org/10.2957/kanzo.56.21

JOURNAL FREE ACCESS

Show abstractHide abstract

The correlation and sensitivity of TaqMan HCV v1.0 (v.1.0) and TaqMan HCV v2.0 (v.2.0) were evaluated by using 239 clinical specimens from 40 patients undergoing Telaprevir-based triple therapy. A correlation study was performed with the specimens from patients at baseline, day 1 and day 3 of the therapy and a clinical sensitivity study was performed on day 3, week 1, week 2, and week 4. Analytical sensitivity was measured by using WHO dilution panels (50, 25, 15, 10, 5 IU/mL and negative). Passing-Bablok regression analysis of the correlation study was y=0.907x+0.093 (r_s=0.985). When clinical sensitivity was evaluated, there were no significant differences between v1.0 and v2.0 by McNemar analysis. Analytical sensitivities of v1.0 and v2.0 were calculated by Probit analysis (95% hit rate, v1.0: 11.59 IU/mL, v2.0: 10.49 IU/mL). Comparison of the treatment outcome (SVR 12) based on RVR (undetectable HCV RNA at week 4) by v2.0 showed almost the same results as those by v1.0. These results showed that correlation and sensitivity of v.2.0 were the same as for v1.0. Therefore, v2.0 can be used for the medical decision points and guideline rules of HCV treatments which have been established based on v1.0.

View full abstract

Download PDF (201K)

Register with J-STAGE for free!